Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>To investigate the survival benefit of concurrent chemoradiotherapy (CCRT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC) during the years of intensity‐modulated radiotherapy (IMRT).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Medical records of 1089 patients with ESCC who received IMRT from January 2005 to December 2017 were retrospectively reviewed. A total of 617 patients received CCRT, 472 patients received radiotherapy (RT) alone. Propensity score matching (PSM) method was used to eliminate baseline differences between the two groups. Survival and toxicity profile were evaluated afterward.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>After a median follow‐up time of 47.9 months (3.2–149.8 months), both overall survival (OS) and progression‐free survival (PFS) of the CCRT group were better than those of the RT alone group, either before or after PSM. After PSM, the 1‐, 3‐, and 5‐year OS of RT alone and CCRT groups were 59.0% versus 70.2%, 27.7% versus 40.5% and 20.3% versus 33.1%, respectively (<i>p</i> < 0.001). The 1‐, 3‐, and 5‐year PFS were 39.4% versus 49.0%, 18.3% versus 30.4% and 10.5% versus 25.0%, respectively (<i>p</i> < 0.001). The rates of ≥ grade 3 leukopenia and radiation esophagitis in the CCRT group were higher than that of RT alone group (<i>p</i> < 0.05). There was no significant difference in the probability of radiation pneumonitis between the two groups (<i>p</i> = 0.167). Multivariate Cox analysis indicated that female, EQD2 ≥60 Gy and concurrent chemotherapy were favorable prognostic factors for both OS and PFS. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Concurrent chemotherapy can bring survival benefits to patients with locally advanced ESCC receiving IMRT. For patients who cannot tolerate concurrent chemotherapy, RT alone is an effective alternative with promising results.</p></section>

What problem does this paper attempt to address?

This paper aims to explore the differences in survival benefits between concurrent chemoradiotherapy (CCRT) and radiotherapy alone (RT) for patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the era of intensity - modulated radiotherapy (IMRT). Specifically, the study retrospectively analyzed the data of 1,089 ESCC patients who received IMRT treatment, and used the propensity score matching (PSM) method to balance the differences in basic characteristics between the two groups of patients, so as to more accurately evaluate the survival advantages and toxic reactions of CCRT relative to RT. ### Research Background Esophageal cancer (EC) is a common malignant tumor with a poor prognosis, and the number of new cases and deaths in China ranks first in the world every year. In China, the main pathological type of esophageal cancer is still squamous cell carcinoma (SCC), accounting for more than 90% of all esophageal cancer patients. Due to the insufficient promotion of annual endoscopic screening, many patients are already in the advanced stage at the time of diagnosis and are not suitable for esophagectomy. For these patients, the standard treatment is usually concurrent chemoradiotherapy (CCRT), but some patients cannot tolerate concurrent chemoradiotherapy for various reasons (such as advanced age, poor general condition, malnutrition, significant weight loss, etc.), so radiotherapy alone (RT) is usually used as an alternative treatment option. ### Research Objectives 1. **Evaluate the survival benefits of CCRT and RT**: By comparing the overall survival (OS) and progression - free survival (PFS) of the two groups of patients, evaluate whether CCRT can bring better survival benefits. 2. **Evaluate the toxic reactions of CCRT and RT**: Compare the acute and late - stage toxic reactions of the two groups of patients after treatment, especially the incidences of grade ≥3 leukopenia and radiation esophagitis. ### Main Findings - **Survival Benefits**: - With a median follow - up time of 47.9 months, the 1 - year, 3 - year, and 5 - year OS in the CCRT group were 70.2%, 40.5%, and 33.1%, respectively, while those in the RT group were 59.0%, 27.7%, and 20.3% (p < 0.001). - The 1 - year, 3 - year, and 5 - year PFS in the CCRT group were 49.0%, 30.4%, and 25.0%, respectively, while those in the RT group were 39.4%, 18.3%, and 10.5% (p < 0.001). - **Toxic Reactions**: - The incidences of grade ≥3 leukopenia and radiation esophagitis in the CCRT group were significantly higher than those in the RT group (p < 0.05). - There was no significant difference in the incidence of radiation pneumonitis between the two groups (p = 0.167). ### Multivariate Cox Regression Analysis - **Favorable Prognostic Factors**: Female, EQD2 ≥60 Gy, and concurrent chemotherapy are favorable prognostic factors for OS and PFS. - **Unfavorable Prognostic Factors**: Stage IVA or IVB disease is associated with a poor survival prognosis. ### Conclusions - **Advantages of CCRT**: Concurrent chemotherapy can bring survival benefits to patients with locally advanced ESCC who receive IMRT treatment. - **Alternative Value of RT**: For patients who cannot tolerate concurrent chemotherapy, radiotherapy alone is still an effective alternative option with good survival results. ### Subgroup Analysis - **Age**: In non - elderly patients (<70 years old), CCRT significantly improved OS (p < 0.001), while in elderly patients (≥70 years old), CCRT did not show a survival advantage (p = 0.808). - **Other Subgroups**: Male, age <70 years old, stage III patients, middle and lower thoracic lesions, patients diagnosed between 2011 - 2017, KPS >70, EQD2 ≥60 Gy, and patients who received static IMRT or VMAT can all benefit from CCRT. ### Discussion - **Treatment Options for Elderly Patients**: Elderly patients have poor tolerance to CCRT, and further research is needed to determine the optimal treatment plan. - **Radiotherapy Dose**: A higher radiotherapy dose (EQD2 ≥60 Gy) is an independent protective prognostic factor for OS and PFS, which is consistent with the results of many studies in recent years. - **Economic and Social Factors**: In China, some patients cannot receive CCRT due to economic and social factors, but even radiotherapy alone can achieve relatively satisfactory survival results. In general, this study provides an important reference basis for the treatment of patients with locally advanced ESCC, especially in the context of the IMRT era, and the survival benefits of concurrent chemotherapy have been confirmed.

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis